Transcripta Bio raises $24M Series A to advance transcriptome-based neurology drugs
What's the deal? Transcripta Bio, a Palo Alto-based AI drug discovery startup, has raised a $24 million Series A. JAZZ Venture PartnersDealroom has a profile for this one. Try Dealroom →, BlueYard CapitalDealroom has a profile for this one. Try Dealroom →, Mayo ClinicDealroom has a profile for this one. Try Dealroom →, and Omnimed backed the round, alongside a group of life sciences family offices.
What's the endgame? Founded in 2023, the 15-person company develops small molecule drugs that modulate gene expression to treat disease. Its platform identifies disease signatures from patient-derived single cell RNA-seq data, then uses an in-house "drug atlas" and AI models to find compounds that can therapeutically shift those signatures.
What's the money for? The funding will advance IND-enabling studies and clinical preparation for Transcripta's neurological disease portfolio, including autism spectrum disorder and facioscapulohumeral muscular dystrophy. The company plans to file an investigational new drug application for Huntington's disease next year and introduce another cohort of programs by the second quarter of 2027.
Why now? Founder and chief executive officer Chris Moxham, a three-decade "drug hunter" formerly at Eli LillyDealroom has a profile for this one. Try Dealroom → and Fulcrum Therapeutics, says the approach depends on recent advances in sequencing, compute power, and lab automation. "This isn't a company you could have built five years ago," he said.
What could go wrong? Drug discovery success rates often fall below 10%. Moxham says de-risking therapies early is key, calling Phase II trials "where the rubber meets the road."
The signal: Transcripta pairs novel molecules with repurposed clinical-stage drugs that carry existing human safety data, potentially shortening timelines. Its early results include entrectinib, an FDA-approved oncology drug, reversing disease in a form of autism, with one patient showing clinical benefit within nine months. At $24 million, the round sits in the 59th percentile by size, a solid but modest bet on a platform Moxham says could apply to "hundreds of diseases."
Read more: GEN
Image credit: Generated with Gemini
